Disclosure: E.R. Phillips: None. M. Lefchak: None. M. Mulcahey: None. K. Prudnikova: 4; Mimecore Therapeutics. M. Marcolongo: 4; Mimecore Therapeutics. INTRODUCTION: Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of disabilities, affecting more than 20 million people in the US. Several biomolecules are depleted in an OA joint including hyaluronic acid (HA) in the synovial fluid and aggrecan in articular cartilage. Current conservative treatments for OA aim to slow the progression of the disease and mediate pain with analgesics, anti-inflammatory drugs, physical therapy and weight loss. We propose to molecularly engineer the damaged cartilage with a novel biomimetic aggrecan (BA) to restore hydration and mechanical function to the cartilage. Aggrecan is a vital component to the hydration and mechanical properties of articular cartilage and is lost during the early stages of degradation. BA mimics the 3-D bottle brush structure and properties of naturally occurring aggrecan and consists of a poly(acrylic acid) (PAA) core with chondroitin sulfate (CS) bristles 1 . As a step toward this objective, here we report the effect of BA concentration, BA molecular size and media ionic strength on BA infiltration into bovine osteochondral plugs and examine BA distribution through the cartilage extracellelar matrix (ECM). METHODS: Osteochondral plugs were cored from the femoral condyles of mature bovine knee joints from Animal Technologies, INC. The osteochondral plugs were immersed in fluorescently labeled biomimetic aggrecan (BA) solutions such that the articular cartilage surface was submerged while limiting the amount of BA solution that could enter through the cut lateral sides of the plug. All BA solutions were synthesized using previously described methods 1 , fluorescently labeled with DCCH (7-Diethylaminocoumarin-3-Carboxylic acid, Hydrazide) 2 , and reconstituted in PBS. The osteochondral plugs were equilibrated in 1X PBS, then immersed in BA solutions for 24 hours with care taken only to expose only the articular surface to the solution. The effect of BA concentration, BA size and charge shielding from ions on the molecular infiltration into the ECM were examined. Plugs soaked in 1X PBS 10mg/mL BA10 (180kDa) solution were used to compare all the BA infiltration effects in this experiment. The remaining groups (n=5) were BA250 (a BA molecule with a 250kDa poly(acrylic acid) core, MW 2,000kDa, instead of a 10kDa core, MW 70kDa); 5mg/mL BA10 concentration, 20mg/mL BA10 concentration; 0.1X PBS solvent, 10X PBS solvent; and a control group (no fluorescence). After the duration of the immersion, the plugs were embedded and cryosectioned. The sections were observed using an Olympus FV1000 confocal microscope through a DAPI filter to detect the fluorescence and the fluorescence was quantified from the images (area percent, Matlab). Significance (α=0.05) was determined using a one-way ANOVA and a Tukey post hoc test was used to determine significance between the different groups. RESULTS: BA molecules passively diffused throughout the cartilage ECM. The BA molecules aggregated around the chondrocytes within the cartilage and were able to diffuse through the cartilage to the tidemark. As the BA concentration increased, the amount of BA which diffused into the cartilage increased. Both size BA molecules infiltrated into the cartilage ECM, however the smaller (BA10, 180kDa) molecule had a higher area percentage than the larger (BA250kDa, 2,000kDa) molecule. There was less infiltration of BA with low ionic strength, 0.1XPBS than with 1 and 10X PBS media, however, little difference between 1 and 10X PBS. DISCUSSION: We have demonstrated that BA can infiltrate normal articular cartilage, distribute throughout the ECM and localize around the chondrocytes. This is a first demonstration of cartilage molecular engineering and has been shown in the absence of cellular activity (ex vivo). The potential is to introduce regenerating molecules like BA, even as drug delivery vehicles, into the cartilage ECM in a minimally invasive manner through synovial joint injections. Here, there is an effect of BA infiltration to the ECM with increasing concentration. The effect is more pronounced between 5 and 10 mg/mL than 10 to 20 mg/mL, indicating that we may be close to a plateau in the amount of BA that normal bovine cartilage can uptake in this model. Both small (180kDa) and large (2,000kDa) BA molecules were able to diffuse into the ECM, although likely steric interactions showed about 20% less infiltration of the larger BA at this time point. Because the BA molecules are highly anionic, the ionic concentration of the media was hypothesized to affect the diffusion into the cartilage ECM. The infiltration at 0.1X PBS was very erratic which may indicate there were not enough ions present to stabilize the BA's charge interactions with the healthy tissue, while there was no significant difference between infiltration of BA in 1 or 10X PBS. Infiltration through the cartilage surface may serve as method to introduce BA into arthritic cartilage to molecularly engineer the tissue and restore its hydration and mechanical properties. SIGNIFICANCE: Pain reduction and joint mobility for patients with OA is a major challenge. Restoration of hydration and mechanical stability of OA cartilage may be approached by injection of BA solutions into the joint space, allowing for passive diffusion of BA into cartilage ECM. This study shows the first ex vivo demonstration of cartilage molecular engineering. 
